Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Jennifer Pulini, Mark Cornfeld, Célèste Lebbé, Shailender Bhatia et al.
Citations
5 citations
Journal
Journal for ImmunoTherapy of Cancer
Topics
Polyomavirus and related diseases
Field-Weighted Citation Impact (FWCI)
5.23
article
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Jennifer Pulini, Mark Cornfeld, Célèste Lebbé, Shailender Bhatia, Henri Montaudié, Caroline Gaudy‐Marqueste, Giovanni Grignani, Michele Guida, Francesco Spagnolo, Cecilia C.S. Yeung, Federica Morano, Roberta Depenni, Francesca Spada, Melissa Amber Burgess, Chuan Tian, Piotr Rutkowski
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal for ImmunoTherapy of CancerVol. 13(8)
Institutions
University of Modena and Reggio Emilia (IT), Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Côte d'Azur (FR), Université Paris Cité (FR), Aix-Marseille Université (FR), Centre Hospitalier Universitaire de Nice (FR), Fred Hutch Cancer Center (US), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), National Institute of Oncology (HU), UPMC Hillman Cancer Center (US), Istituto Tumori Bari (IT), Ospedale Policlinico San Martino (IT), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Candiolo Cancer Institute (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), European Institute of Oncology (IT), University of Genoa (IT), Incyte (United States) (US)
Funders
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Fred Hutchinson Cancer Research Center, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Incyte, Advanced Accelerator Applications, Springworks Therapeutics, Eisai, Servier, PharmaMar, LEO Pharma, EMD Serono